What are the different types of immunotherapy of prostate cancer?

There are three types of immunotherapy for prostate cancer. Active immunotherapy uses therapy designed to start the responses of the body's immune system. Passive immunotherapy implements methods created by laboratories such as artificial antibodies, for cancer treatment and specific immunotherapy focuses on a specific cell without killing other cells. These three different types of immunotherapy work differently as treatment of prostate cancer. These monoclonal antibodies (MABS) are created in the laboratory. Conjugated MAB are antibodies that also contain a type of toxin, such as treatment of chemotherapy or small amounts of radiation. They are looking for and destroying prostate cancer cells without affecting normal healthy cells. Naked MAB does not contain toxins or do not work either by indicating cancer cells for destruction of the immune system or preventing the growth of cancer cells.

Aimunotherapy CTIVE for prostate cancer is the treatment of cancer that relies on the immune system to attack cancer cells in the prostate. Like ImUnion causes an immune system to protect against diseases and viruses, and cancer vaccines cause an immune system to combat cancer cells. Although these vaccines are often created laboratories, they are specially designed to trigger lymphocyte production. In many cases, specific cells of prostate cancer are taken from the patient and combined with a vaccine. Cancer proteins bind to vaccine cells, allowing the vaccine to help the immune system recognize cancer cells as foreign and destroy them.

Specific immunotherapy of prostate cancer is more targeted therapy. Many cases of specific immunotherapy combine passive or active immunotherapy with traditional treatments such as radiation and chemotherapy. Other methods are used to indicate prostate cancer cells and make them more vulnerable to traditional treatment. This type of immunotherapy is often used when prostate cancer is in advancedstages. Advanced cancer phases are often more difficult to heal because they grow faster and can more easily metastasize.

Prostate cancer immunotherapy is often not chosen as the first path of prostate cancer treatment, which is still in the early stages. Advanced or repeating prostate cancer often does not respond to traditional treatment methods. Prostate aggressive cancer is more resistant than its non -aggressive counterparts. For this reason, immunotherapy is often used when other methods fail or are not ideal. In addition, immunotherapy can be designed when prostate cancer has caused more tumors to appear rapidly.